132 related articles for article (PubMed ID: 22653101)
1. [Radiometabolic therapy for metastatic thyroid carcinoma: overview of the literature and rational bases for the use of recombinant human TSH].
Testori O; Bagnasco M; Banti E; Bombardieri E; Dottorini ME; Fugazzola L; Maffioli L; Perotti G; Rubello D; Seregni E
Minerva Med; 2012 Jun; 103(3):209-18. PubMed ID: 22653101
[TBL] [Abstract][Full Text] [Related]
2. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience.
Perros P
J Endocrinol Invest; 1999; 22(11 Suppl):30-4. PubMed ID: 10727003
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine ablation of post-surgical thyroid remnants after preparation with recombinant human TSH: why, how and when.
Barbaro D; Boni G
Eur J Surg Oncol; 2007 Jun; 33(5):535-40. PubMed ID: 17337154
[TBL] [Abstract][Full Text] [Related]
5. Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years.
Molinaro E; Pieruzzi L; Viola D
J Endocrinol Invest; 2012; 35(6 Suppl):16-20. PubMed ID: 23014069
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma.
Pitoia F; Tamer EE; Schere DB; Passerieu M; Bruno OD; Niepomniszcze H
Medicina (B Aires); 2006; 66(2):125-30. PubMed ID: 16715760
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer.
Kovatcheva RD; Hadjieva TD; Kirilov GG; Lozanov BS
Nucl Med Rev Cent East Eur; 2004; 7(1):13-9. PubMed ID: 15318305
[TBL] [Abstract][Full Text] [Related]
8. [Recombinant human TSH stimulation in radioiodine treatment of disseminated differentiated thyroid cancer--update of current and our own experiences].
Hasse-Lazar K; Handkiewicz-Junak D; Roskosz J; Szpak-Ulczok S; Krajewska J; Jurecka-Lubieniecka B; Jarzab B
Endokrynol Pol; 2006; 57(4):445-50. PubMed ID: 17006851
[TBL] [Abstract][Full Text] [Related]
9. The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases.
De Klerk JM; Oyen WJ
Minerva Endocrinol; 2009 Mar; 34(1):57-69. PubMed ID: 19209128
[TBL] [Abstract][Full Text] [Related]
10. The widened use of exogenous stimulation with recombinant human TSH to treat metastatic thyroid carcinoma in Italy.
Maffioli L; Florimonte L; Fugazzola L; Banti E; Bagnasco M; Dottorini ME; Perotti G; Rubello D; Seregni E; Bombardieri E; Testori O
Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):476-84. PubMed ID: 23069926
[TBL] [Abstract][Full Text] [Related]
11. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
13. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
14. [Current trends in treatment and follow-up of patients with differentiated thyroid carcinoma - experience with the use of recombinant human thyrotropin].
Macková M; Vlček P
Vnitr Lek; 2013 Feb; 59(2):106-12. PubMed ID: 23461399
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine therapy of metastatic lesions of differentiated thyroid cancer.
Luster M; Hänscheid H; Freudenberg LS; Verburg FA
J Endocrinol Invest; 2012; 35(6 Suppl):21-9. PubMed ID: 23014070
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): whole-body scanning with iodine-131.
Reiners C; Luster M; Lassmann M
J Endocrinol Invest; 1999; 22(11 Suppl):17-24. PubMed ID: 10727001
[TBL] [Abstract][Full Text] [Related]
17. The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: a roundtable discussion.
Schlumberger MJ; Incerti C; Pacini F; Reiners C
J Endocrinol Invest; 1999; 22(11 Suppl):35-41. PubMed ID: 10727004
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis.
Eustatia-Rutten CF; Smit JW; Romijn JA; van der Kleij-Corssmit EP; Pereira AM; Stokkel MP; Kievit J
Clin Endocrinol (Oxf); 2004 Jul; 61(1):61-74. PubMed ID: 15212646
[TBL] [Abstract][Full Text] [Related]
19. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma.
Luster M; Sherman SI; Skarulis MC; Reynolds JR; Lassmann M; Hänscheid H; Reiners C
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1371-7. PubMed ID: 12856155
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose.
Campennì A; Amato E; Laudicella R; Alibrandi A; Cardile D; Pignata SA; Trimarchi F; Ruggeri RM; Auditore L; Baldari S
Endocrine; 2019 Jul; 65(1):132-137. PubMed ID: 30875058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
